UNSPSC 51313409: Doxylamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95QB77JKPL, chemically known as pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)- but generally known as doxylamine, which bears US NIH Compound Identifier 3162. European Medicines Agency schedules Doxylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06394MIG. The term DOXYLAMINE is an International Non-Proprietary Name.

UNSPSC 51313409 Doxylamine is a Commodity code that covers pharmaceutical products including over-the-counter and generic medications purchased by state and local health and human services agencies, county health departments, and multistate cooperative purchasing consortiums to support community health initiatives, pharmacy benefit programs, and emergency response systems. State and local procurement under this code encompasses bulk purchases of pharmaceuticals and related health products with quarterly or annual delivery schedules, typically requiring vendors to maintain compliance with FDA manufacturing standards, Drug Supply Chain Security Act requirements, and current Good Manufacturing Practices, along with standard commercial insurance and workplace certifications.

Recent activity shows solicitation by health agencies across multiple jurisdictions and cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county's Community Health Building and a fixed-fee contract structure with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling future formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Geographic activity centers on the Southeast and Midwest, with multistate cooperative vehicles extending procurement scope across multiple jurisdictions.